Advanced in Endometrial Stromal Sarcoma

Noriomi Matsumura

Osaka, JP 
Advanced in Endometrial Stromal Sarcoma
Osaka, JP 
OverviewLocationsClinical Research

Overview

Noriomi Matsumura practices in Osaka, Japan. Matsumura is rated as an Advanced expert by MediFind in the treatment of Endometrial Stromal Sarcoma. Their top areas of expertise are Ovarian Cancer, Endometrial Cancer, Macrophagic Myofasciitis, Hysterectomy, and Oophorectomy.

Their clinical research consists of co-authoring 240 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Endometrial Stromal Sarcoma.

Locations

Osaka, Japan
Other Locations
Tokyo, Japan
Sayama, 5898511, Japan
Kinokawa, 6496493, Japan
Sayama, 5898511, Japan
Higashi-osaka, Japan
Japan
Kyoto, Japan
Fukushima, 9601295, Japan
Kawahara, 6068507, Japan
Saitama, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3

240 Total Publications

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for colorectal cancer, trastuzumab deruxtecan for breast cancer, and acalabrutinib for mantle cell lymphoma.
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for colorectal cancer, trastuzumab deruxtecan for breast cancer, and acalabrutinib for mantle cell lymphoma.
Journal: International journal of clinical oncology
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Matsumura's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile